| Identification | Back Directory | [Name]
ARN-2966 | [CAS]
102212-26-0 | [Synonyms]
2-PMAP
ARN-2966
ARN2966(2-PMAP)
ARN-2966;ARN 2966
2-PMAP >=98% (HPLC)
Phenol, 2-[(2-pyridinylmethyl)amino]- | [Molecular Formula]
C12H12N2O | [MDL Number]
MFCD24550644 | [MOL File]
102212-26-0.mol | [Molecular Weight]
200.24 |
| Chemical Properties | Back Directory | [Melting point ]
130 °C(Solv: chloroform (67-66-3); hexane (110-54-3)) | [Boiling point ]
354.4±27.0 °C(Predicted) | [density ]
1.241±0.06 g/cm3(Predicted) | [storage temp. ]
Desiccate at -20°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [pka]
10.22±0.35(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Biological Activity]
arn2966 is a potent post-transcriptional modulator of amyloid precursor protein (app) expression in transfected cho cells. the cho cell can produce app.[1]app is the amyloid precursor protein of alzheimer’s disease. alzheimer’s disease is a progressive dementia with the symptoms of neuronal degeneration, synaptic loss, and the deposition of amyloid fibrils in the brain. ab protein is the major constituent of the amyloid . then the ab protein derives from the amyloid precursor protein (app). it has been proved that app can stimulate neurite outgrowth in vitro. [2]the modulation of app expression of the arn2966 functions as a post-transcriptional modulation,which is different from other mechanisms such as inhibition of secretases. arn2966 showed dose dependant inhibition of a?40 and a?42 productions in app751sw transfected cho cells (ic50<1 mm for a?40), along with lowering the level of app and c83, and c99 peptides, while the level of app mrna was unaffected..[1]there has been ad transgenic mice model proved arn2966’s efficacy and tolerability in vivo. through the treatment of arn2966, the memory of mice has been improved and a load in the brain has been reduced. | [References]
[1] ayodeji asuni ,xu kevin , etal. , an app translation modulator arn2966 reduces beta-amyloid deposition and prevents memory deficits in alzheimer's disease transgenic mice. alzheimer's & dementia: the journal of the alzheimer's association, july 2012volume 8, issue 4, supplement, page s744 ;
[2]williamson tg1, mok ss, henry a, etal. , secreted glypican binds to the amyloid precursor protein of alzheimer's disease (app) and inhibits app-induced neurite outgrowth. j biol chem. 1996 dec 6;271(49):31215-21. |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|